Peptide News Digest

Wegovy HD 7.2 mg CHMP Approval, Foundayo Week 6 IQVIA ~17K, ASCO May 26 Press Briefing, Memorial Day Conference Week, TRIUMPH-1 Sunday Wrap

Wegovy HD 7.2 mg CHMP positive opinion, Foundayo Week 6 IQVIA ~17K vs Wegovy pill ~142K, ASCO May 26 embargoed press briefing, Memorial Day dual-meeting week.

6 stories · Covering regulatory, industry

Editor's Note

Sunday digest sits at the front of a Memorial-Day-week calendar with two major peptide-relevant medical congresses landing back-to-back: EASL 2026 in Barcelona opens Wednesday May 27, then ASCO 2026 in Chicago opens Friday May 29. The CHMP positive opinion for Wegovy HD 7.2 mg (the high-dose injectable) on May 22 — separate from the Wegovy pill CHMP that headlined the same day — completes Novo Nordisk's EU regulatory cycle for both the higher-dose injectable (STEP UP 20.7% weight loss) and the oral formulation, with Q3 2026 EU launches expected for both. The May 22-23 IQVIA tracker landed Foundayo at roughly 17,000 prescriptions for the week ending May 15 versus Wegovy pill at approximately 142,000 — Lilly's first weekly print above 15K, narrowing but not closing the trajectory gap with Novo's oral semaglutide. ASCO's May 26 embargoed virtual press briefing previews Late-Breaking Abstracts before the May 29 meeting opens, with the peptide-oncology slate (Bicycle Duravelo-2 Phase 2, Avacta AVA6000 Phase 1a/1b, Sapience lucicebtide GBM, BriaCell Bria-IMT 16.6 mo OS, Corbus CRB-701 Nectin-4 ADC) anchoring the meeting. TRIUMPH-1's Sunday news consolidation extended the broadly favorable analyst read into the weekend press cycle with Leerink, RBC, and the popular health press uniformly framing the data as 'raising the bar' for the obesity-pharmacology field. Sunday news flow was genuinely thin — this leaner six-item digest reflects the actual fresh-news supply rather than padding with synthesis pieces already covered earlier in the week.

Regulatory

Novo Nordisk Wegovy HD 7.2 mg CHMP Positive Opinion (May 22): EMA Recommends EU Approval for High-Dose Injectable Semaglutide With 20.7% STEP UP Weight Loss, Q3 2026 EU Launch

Novo Nordisk announced May 22 that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency adopted a positive opinion recommending marketing authorization of Wegovy 7.2 mg in a single-dose pen for adults living with obesity. Wegovy 7.2 mg is the high-dose once-weekly injectable formulation already available in the US as Wegovy HD. The STEP UP Phase 3 trial demonstrated 20.7% mean weight loss with the 7.2 mg dose, with approximately one in three participants experiencing ≥25% weight loss; in the STEP UP T2D trial, the same dose produced 14.1% mean weight loss in adults with obesity and type 2 diabetes. Novo expects to launch Wegovy 7.2 mg in the EU in Q3 2026. The CHMP opinion arrived the same day as the parallel positive recommendation for Wegovy pill (oral semaglutide 25 mg) — completing Novo's twin EU regulatory wins for the higher-dose injectable and the oral formulation simultaneously.

#novo-nordisk #wegovy-hd #wegovy-7-2 #chmp #ema-eu-approval #step-up #high-dose-semaglutide
Industry

Foundayo IQVIA Week-Ending-May-15 Tracker: ~17,000 Prescriptions vs Wegovy Pill ~142,000 — Lilly's First Above-15K Print Narrows but Doesn't Close the Trajectory Gap

IQVIA's weekly prescription tracker for Foundayo (orforglipron) hit approximately 17,000 prescriptions for the week ending May 15, 2026, per Citi's Friday client note — Lilly's first above-15,000 weekly print since the April 6 launch. The week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5), and ~17,000 in the new print. Novo Nordisk's Wegovy pill recorded roughly 142,000 prescriptions in the same week — the trajectory gap is narrowing as Foundayo's PBM coverage activates at the largest US plans but still remains 8.3x the Foundayo volume. Citi maintains $146M Foundayo Q2 revenue and $1.6B 2026 full-year estimates; the IQVIA print supports the trajectory. Lilly's late-May TV-advertising launch may amplify the next leg of Foundayo growth heading into mid-June.

#foundayo #orforglipron #iqvia #wegovy-pill #week-6 #citi #weekly-tracker
Industry

ASCO 2026 Embargoed Virtual Press Briefing Tuesday May 26 — Late-Breaking Abstracts Pre-Meeting Reveal for Credentialed Media Ahead of May 29 Opening

ASCO will hold an embargoed virtual press briefing for credentialed media on Tuesday May 26 to preview Late-Breaking Abstracts being presented during the Annual Meeting that opens Friday May 29 in Chicago. Late-Breaking Abstracts are submitted after the standard abstract deadline and contain data that would not have been available at the regular submission cycle — typically the highest-impact data of the meeting. The briefing covers presentations across the full ASCO program including the peptide-oncology slate that landed in the May 21 abstract release: Bicycle Therapeutics' Duravelo-2 Phase 2 (65% ORR/58% BICR-confirmed), Avacta's AVA6000 Phase 1a/1b in salivary gland cancer (90% disease control rate), Sapience Therapeutics' lucicebtide Phase 2 GBM, BriaCell's Bria-IMT 16.6-month Phase 2 OS, Corbus Pharmaceuticals' CRB-701 Nectin-4 ADC, and Crinetics' CRN09682 SSTR2 NDC BRAVESST2. The May 26 embargo lifts late afternoon to feed press coverage into the Wednesday-Thursday cycle.

#asco-2026 #late-breaking-abstracts #press-briefing #may-26-embargo #peptide-oncology
Industry

Memorial Day Conference Week (May 25-31): EASL Barcelona Wednesday + ASCO Chicago Friday Open Back-to-Back, Most Concentrated Peptide-Meeting Cycle Since AACR 2026

The Memorial Day week landing pad in the medical-conference calendar is unusually peptide-heavy. Monday May 25 is the US Memorial Day federal holiday. EASL 2026 (European Association for the Study of the Liver) opens Wednesday May 27 in Barcelona running through Saturday May 30, with Novo Nordisk's ESSENCE Phase 3 liver-safety analyses, Eli Lilly's retatrutide MASLD Phase 3 enrollment status, Boehringer survodutide SYNCHRONIZE-1 forward-look, and MetaVia vanoglipel + resmetirom MASH preclinical work anchoring the peptide-relevant program. ASCO 2026 (American Society of Clinical Oncology) opens Friday May 29 in Chicago running through Tuesday June 2 with the peptide-oncology slate landing across all five days. Combined, the two meetings concentrate the most peptide-mechanism data of any week in 2026 — MASH plus oncology back-to-back. Practitioner press will be split across the two meetings.

#easl-2026 #asco-2026 #memorial-day-week #barcelona #chicago #mash-meeting #peptide-oncology
Industry

TRIUMPH-1 Sunday Coverage Consolidation: Broadly Favorable Across Leerink, RBC, Mainstream Health Press Through the Weekend Cycle

The Sunday coverage cycle on Lilly's Thursday TRIUMPH-1 readout settled into broadly favorable consensus. Leerink's David Risinger characterized the data as 'raising the bar for future novel obesity drug developers'; RBC Capital's Trung Huynh framed it as a 'clean win for Lilly'; Dan Skovronsky (Lilly CSO) called 30% weight loss 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' Mainstream press coverage — NPR, BioPharma Dive, CNBC, Good Morning America — uniformly led with the bariatric-surgery-territory framing (45.3% of 12 mg participants reaching ≥30% weight loss). The dysesthesia signal (12.5% at 12 mg) registered in pharma-industry coverage and analyst commentary but received minimal mainstream-press attention. The TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + CVD) readouts later in 2026 are the next inflection points; the NDA filing follows in Q4 2026 or Q1 2027.

#retatrutide #triumph-1 #weekend-press-cycle #leerink #rbc #skovronsky #media-coverage
Industry

Wegovy Pill Cumulative US Prescriptions Trajectory Going Into Memorial Day Week: 2M+ Confirmed May 18, Now Approaching 2.15M

Cumulative US Wegovy pill prescriptions, as disclosed in Novo Nordisk CEO Maziar Doustdar's May 14 commentary (>1M) and EVP Larsen's May 18 commentary on CNBC (>2M), continued to trend upward through the Memorial-Day-week lead-in. Weekly Wegovy pill volume of approximately 142,000 for the week ending May 15 — slightly above the prior week's 137,000 after the brief mid-May decline — suggests cumulative US prescriptions are now in the 2.1-2.15M range. The Wegovy pill launch (January 5, 2026) trajectory continues to outpace the comparable Wegovy injectable launch (June 2021), positioning Novo for the projected H2 2026 EU launches in UK, Germany, and Denmark. The Wegovy HD (7.2 mg injectable) CHMP positive opinion announced May 22 adds the high-dose franchise to the EU portfolio.

#wegovy-pill #cumulative-prescriptions #novo-nordisk #memorial-day #iqvia #international-rollout